Effect of Low Molecular Weight Heparin on Survival of Stage I, II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.

Trial Profile

Effect of Low Molecular Weight Heparin on Survival of Stage I, II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Embolism and thrombosis; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TILT
  • Most Recent Events

    • 15 Sep 2016 Last checked against ClinicalTrials.gov record.
    • 01 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2010 Planned end date changed from 1 Jun 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top